---
document_datetime: 2025-05-08 19:40:16
document_pages: 12
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/carvykti-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: carvykti-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 7.0706635
conversion_datetime: 2025-12-27 21:17:58.383072
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## CARVYKTI

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary        |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------|
| II/0034              | Submission of an updated RMP version 6.1 in order to add a new important identified risk of 'Secondary malignancy of T-cell origin', to change the important potential risk of 'Second primary malignancies' to 'Second primary malignancy except secondary malignancy of T-cell origin', and to include an | 25/04/2025                          | n/a                                         |                                  | Not applicable |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | additional pharmacovigilance activity for testing of secondary malignancies of T-cell origin, following the PRAC recommendation for the Secondary malignancy of T-cell origin signal (EPITT no: 20040). The final version of the RMP (v6.1) includes consolidation of recent approved parallel RMP version 5.6 in procedure EMEA/H/C/005095/II/0036 and further updates the important potential risk of 'Second primary malignancy except secondary malignancy of T-cell origin' to 'Secondary malignancy except those of T cell and myeloid origin' as matter of combination of the two RMP versions. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH   |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0036 | Update of sections 4.8, and 5.1 of the SmPC in order to update the list of adverse drug reactions (ADRs), and update clinical efficacy and safety information based on second interim analysis from study 68284528MMY3002 (CARTITUDE-4); this is a phase 3 randomized study comparing ciltacabtagene autoleucel, a chimeric antigen receptor T cell (CAR- T) therapy directed against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in subjects with relapsed and                                                                                                                                                                                                                                                                                                                         | 27/03/2025 | SmPC and PL | Myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML), including cases with fatal outcomes, have occurred in patients after CARVYKTI infusion. As well, the PI has been updated to include 'Secondary malignancy of myeloid origin' with a common frequency and provide updates of the efficacy data of longer follow up of the comparative study for the approval of carvykti. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                     | furthermore, the procedure updates section 4.4 and 4.8 of the SmPC to implement safety information regarding secondary malignancy of myeloid origin included with common frequency as also discussed during the parallel PSUR (EMEA/H/C/PSUSA/00011000/202408). The package leaflet has been updated accordingly. Annex II is also updated to reflect the changes in the educational material regarding risk of secondary malignancies of myeloid origin. The RMP version 5.6 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives for Germany, Greece, Slovenia and United Kingdom(Northern Ireland) in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/11000 /202408 | Periodic Safety Update EU Single assessment - ciltacabtagene autoleucel                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 13/03/2025 | n/a | PRAC Recommendation - maintenance |
| II/0037             | B.II.c.3.b - Change in source of an excipient or reagent with TSE risk - Change or introduction of a TSE risk material or replacement of a TSE risk material from a different TSE risk material, not covered by a TSE certificate of suitability                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 27/02/2025 | n/a |                                   |
| IB/0039             | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 10/02/2025 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0040             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                      | 04/02/2025   | n/a   |              |                                                                  |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|--------------|------------------------------------------------------------------|
| II/0035             | B.II.d.1.f - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product                                                                                                                                                                                     | 30/01/2025   | n/a   |              |                                                                  |
| IB/0038             | B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation                                                                                                                                                                                                                                                                                                      | 28/01/2025   | n/a   |              |                                                                  |
| IB/0031             | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                             | 11/10/2024   | n/a   |              |                                                                  |
| PSUSA/11000 /202402 | Periodic Safety Update EU Single assessment - ciltacabtagene autoleucel                                                                                                                                                                                                                                                                                                                                  | 03/10/2024   | n/a   |              | PRAC Recommendation - maintenance                                |
| IB/0029/G           | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 19/09/2024   | n/a   |              |                                                                  |
| II/0027/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                       | 19/09/2024   |       | Annex II and | The Annex II and IIIB have been updated with the following site: |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.3 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing for a biol/immunol product and any of the test methods is a biol/immunol/immunochemical method B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing   |            |     | PL   | The new manufacturing and batch release site for active substance/finished product: Janssen Pharmaceutica Technologiepark-Zwijnaarde 73 9052, Ghent Belgium   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0032 | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 22/08/2024 | n/a |      |                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| IAIN/0030   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 26/07/2024   |            | SmPC, Annex II and PL            |                                                                     |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|---------------------------------------------------------------------|
| II/0023     | B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 25/04/2024   | n/a        |                                  |                                                                     |
| II/0021     | Extension of indication to include treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 1 prior therapy, including an IMiD and a PI, have demonstrated disease progression on the last therapy and are refractory to lenalidomide for CARVYKTI, based on interim results from study MMY3002 listed as a specific obligation (SOB/006) in the Annex II. This is an ongoing, Phase 3, randomized, open-label, multicentre study to determine whether treatment with cilta-cel provides an efficacy benefit compared to standard therapy in participants with relapsed and lenalidomide- refractory multiple myeloma. As a consequence, sections 4.1, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The SOB is considered fulfilled and therefore deleted from Annex II. Version 4.3 of the RMP has also been submitted. In addition, the MAH took the opportunity to update Annex II of the PI. As part of the application the MAH is requesting a 1- year extension of the market protection. | 22/02/2024   | 19/04/2024 | SmPC, Annex II, Labelling and PL | Please refer to Scientific Discussion 'Carvykti-H-C-5095-II- 0021'. |

<div style=\"page-break-after: always\"></div>

|                     | Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                            |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/11000 /202308 | Periodic Safety Update EU Single assessment - ciltacabtagene autoleucel                                                                                                                                                                                                | 11/04/2024 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| R/0025              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                | 25/01/2024 | 11/03/2024 |             | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for CARVYKTI, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion and without prejudice to any of the ongoing scientific assessments. |
| PSUSA/11000 /202302 | Periodic Safety Update EU Single assessment - ciltacabtagene autoleucel                                                                                                                                                                                                | 12/10/2023 | 07/12/2023 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/11000/202302.                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0018             | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method | 09/11/2023 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IB/0024             | B.II.g.4.b - Changes to an approved change management protocol - Minor changes that do not change the strategy defined in the protocol                                                                                                                                 | 27/10/2023 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| IA/0022   | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                              | 25/07/2023   | 07/12/2023   | SmPC   |           |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------|-----------|
| II/0019   | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method                                                                                                                                     | 20/07/2023   | n/a          |        |           |
| II/0016   | B.I.b.1.e - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a specification parameter which may have a significant effect on the overall quality of the AS and/or the FP                                                                                                                                                               | 22/06/2023   | n/a          |        |           |
| IB/0020   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                               | 19/06/2023   | n/a          |        |           |
| IB/0015/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other | 28/04/2023   | n/a          |        | variation |

<div style=\"page-break-after: always\"></div>

| II/0005   | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS                                                                                                        | 30/03/2023   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0014   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                  | 28/03/2023   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| R/0008    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                 | 26/01/2023   | 24/03/2023 | SmPC, Annex II and PL | The CAT/CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for CARVYKTI, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| IB/0010/G | This was an application for a group of variations. B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for | 17/03/2023   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|                     | batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |             |                                                                                                                                                                                                                                                                                                                                              |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/11000 /202208 | Periodic Safety Update EU Single assessment - ciltacabtagene autoleucel                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 16/03/2023 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                            |
| N/0013              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                | 09/03/2023 | 07/12/2023 | PL          |                                                                                                                                                                                                                                                                                                                                              |
| IB/0012             | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                      | 17/02/2023 | n/a        |             |                                                                                                                                                                                                                                                                                                                                              |
| IB/0011             | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                                     | 14/02/2023 | n/a        |             |                                                                                                                                                                                                                                                                                                                                              |
| II/0004/G           | This was an application for a group of variations. Grouped application comprising two type II variations as follows: - Update of section 4.4 of the SmPC in order to add a new warning on increased risk of severe/fatal COVID-19 infections following Covid-19 signal evaluation from the ongoing study 68284528MMY3002 (CARTITUDE-4) based on a cumulative review of all clinical trials, registries and literature. - Update of section 4.4 of the SmPC in order to add a new warning Risk of severe bleeding in the context | 15/12/2022 | 24/03/2023 | SmPC and PL | SmPC new text: Patients who develop HLH may have an increased risk of severe bleeding. Patients treated with CARVYKTI may be at an increased risk of severe/fatal COVID-19 infections. Patients should be counselled on the importance of prevention measures. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|         | (HLH) following a signal evaluation from the ongoing study 68284528MMY3002 (CARTITUDE-4) based on cumulative review of all clinical trials, registries and literature. The Package Leaflet is updated accordingly. The RMP version 2.2 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                             |            |            |                        |                                                                               |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------|
| II/0003 | Update of sections 4.4 and 4.8 of the SmPC in order to update the existing warnings on cytokine release syndrome (CRS), neurologic toxicities and grading of related events and to update the list of adverse drug reactions (ADRs) based on previously reviewed data from studies MMY2001 and MMY2003, and an additional internal characterisation of neurotoxicity risk; the Package Leaflet is updated accordingly. The RMP version 2.1 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 15/12/2022 | 24/03/2023 | SmPC, Labelling and PL | For more information, please refer to the Summary of Product Characteristics. |
| IB/0007 | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 24/11/2022 | n/a        |                        |                                                                               |

<div style=\"page-break-after: always\"></div>

|         | of the AS                                                                                                                                                                                                                                                  |            |     |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0006 | B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                                     | 10/11/2022 | n/a |
| II/0002 | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol | 10/11/2022 | n/a |
| IB/0001 | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                        | 11/10/2022 | n/a |